GRAIL, LLC (GRAL)vsWaters Corporation (WAT)
GRAL
GRAIL, LLC
$52.29
+7.48%
HEALTHCARE · Cap: $2.00B
WAT
Waters Corporation
$302.32
+0.13%
HEALTHCARE · Cap: $29.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 2051% more annual revenue ($3.17B vs $147.17M). WAT leads profitability with a 20.3% profit margin vs -2.8%. WAT earns a higher WallStSmart Score of 60/100 (C).
GRAL
Avoid34
out of 100
Grade: F
WAT
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GRAL.
Margin of Safety
-349.9%
Fair Value
$73.17
Current Price
$302.32
$229.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 33.8%
Safe zone — low bankruptcy risk
Every $100 of equity generates 29 in profit
Keeps 20 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -16.1% — below average capital efficiency
Moderate valuation
Earnings declined 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : GRAL
The strongest argument for GRAL centers on Price/Book. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : WAT
The primary concerns for WAT are P/E Ratio, EPS Growth.
Key Dynamics to Monitor
GRAL profiles as a turnaround stock while WAT is a mature play — different risk/reward profiles.
GRAL is growing revenue faster at 14.0% — sustainability is the question.
WAT generates stronger free cash flow (126M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WAT scores higher overall (60/100 vs 34/100), backed by strong 20.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a pioneering biotechnology firm focused on revolutionizing cancer detection through its state-of-the-art blood tests designed for early diagnosis. With its proprietary genomic technologies, GRAIL is at the forefront of the multi-cancer early detection (MCED) market, empowering individuals with essential information for proactive healthcare management. The company's dedication to advancing precision medicine not only aims to improve patient outcomes but also addresses critical gaps in cancer screening and diagnostics, positioning GRAIL as a crucial player in the future landscape of oncology.
Visit Website →Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?